XML 74 R7.htm IDEA: XBRL DOCUMENT v3.25.2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Cash flows from operating activities:    
Net loss $ (9,383) $ (10,445)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation 769 691
Depreciation and amortization 87 91
Loss from equity method investment 0 100
Amortization/accretion on marketable securities (61) (285)
Changes in operating assets and liabilities:    
Accounts receivable 399 0
Prepaid and other current assets 63 (352)
Other assets 90 83
Accounts payable, accrued liabilities and other liabilities (1,322) (2,193)
Net cash used in operating activities (9,358) (12,310)
Cash flows from investing activities:    
Purchase of marketable securities (9,180) (28,515)
Sale of marketable securities 19,144 46,764
Purchase of property and equipment (28) 0
Investment in Impilo Therapeutics 0 (100)
Net cash provided by investing activities 9,936 18,149
Cash flows from financing activities:    
Proceeds from exercise of options 8 0
Tax withholding payments on net share settlement equity awards (253) (142)
Net proceeds from issuance of common stock 286 32
Net cash provided by (used in) financing activities 41 (110)
Effect of exchange rate changes on cash 7 (29)
Net increase in cash and cash equivalents 626 5,700
Cash and cash equivalents at beginning of period 16,209 22,593
Cash and cash equivalents at end of period $ 16,835 $ 28,293